Trial reportNeuro-oncology2015
A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study.
Registry-linked trialOpen access · bronzeAbstract readClinical Trial, Phase IIMulticenter StudyRandomized Controlled Trial
In one paragraph
Trial report in Neuro-oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00458601 (A Phase II Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme), which is not on this map. Cited by 259 papers, 10 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
259citing papers in PubMed, 10 pooled it
30.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase II Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme
Who cites it
259 citing papers in PubMed, 10 syntheses or guidelines pooled it, 414 citations in OpenAlex.
- Receptor tyrosine kinase targeted therapies in glioblastoma: a systematic review.Frontiers in medicine · 2026Pooled it
- Efficacy and Safety of EGF/EGFR Vaccines in EGFR-Driven Solid Tumors: A Systematic Review and Meta-Analysis of Controlled and Single-Arm Studies.Cancer medicine · 2025Pooled it
- Efficacy of vaccination therapy in newly diagnosed and recurrent glioblastoma patients: a meta-analysis.BMC cancer · 2025Pooled it
- A systematic review of immunotherapy in high-grade glioma: learning from the past to shape future perspectives.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024Pooled it
- Research hotspots and trend of glioblastoma immunotherapy: a bibliometric and visual analysis.Frontiers in oncology · 2024Pooled it
- Glioblastoma Immunotherapy: A Systematic Review of the Present Strategies and Prospects for Advancements.International journal of molecular sciences · 2023Pooled it
- Personalised therapeutic approaches to glioblastoma: A systematic review.Frontiers in medicine · 2023Pooled it
- Impact of molecular and clinical variables on survival outcome with immunotherapy for glioblastoma patients: A systematic review and meta-analysis.CNS neuroscience & therapeutics · 2022Pooled it
- Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of emerging developments in the management of newly diagnosed glioblastoma.Journal of neuro-oncology · 2020Pooled it
- Anti-epidermal growth factor receptor therapy for glioblastoma in adults.The Cochrane database of systematic reviews · 2020Pooled it
- Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020Trial
- Immunotherapy for Newly Diagnosed Glioblastoma: Current Evidence and Future Perspectives.Journal of personalized medicine · 2026Review
- Impact of dynamic beam delivery of intensity-modulated radiation therapy and volumetric modulated arc therapy on circulating immune cell exposure in glioma.Physics and imaging in radiation oncology · 2026Article
- Article
- Targeting immunosuppressive network in glioblastoma: Emerging strategies to overcome immunodeficiency and enhance therapeutic efficacy.Acta pharmaceutica Sinica. B · 2026Review
- Disrupting PDGFRA-driven immune evasion in glioma: vaccine-based strategies on the horizon.Frontiers in oncology · 2026Review
- Next-generation immunotherapy biologics for glioblastoma.Frontiers in immunology · 2026Review
- Chimeric antigen receptor macrophages therapy for glioblastoma: challenges and opportunities from preclinical evidence to clinical translation.Frontiers in immunology · 2026Review
- Current Status and Evolution of Immunotherapy in Glioma Management.International journal of medical sciences · 2026Review
- Biomarkers for predicting and monitoring the efficacy of cancer vaccines.Frontiers in oncology · 2026Review
199 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
18 authors at 12 institutions in 1 country.
James SchusterHospital of the University of Pennsylvania, Philadelphia, Pennsylvania (J.S.); The Neurological Institute of Columbia University, New York, New York (R.K.L.); Stanford Cancer Center, Stanford, California (L.D.R.); Duke University Medical Center, Durham, North Carolina (D.A.R., G.E.A., D.D.B., J.H.S.); Evanston Northwestern Healthcare, Evanston, Illinois (N.A.P.); University of Texas M.D. Anderson Cancer Center, Houston, Texas (M.D.G.); University of Washington School of Medicine, Seattle, Washington (M.M.M.); Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah (R.J.); Yale University School of Medicine, New Haven, Connecticut (J.M.B); University Hospital-Case Medical Center & Case Comprehensive Cancer Center, Cleveland, Ohio (A.S.); Scott Cruickshank & Associates, Inc., Santa Barbara, C alifornia (S.C.); Celldex Therapeutics, Inc., Hampton, New Jersey (J.A.G., T.K., T.A.D.); University of Texas M.D. Anderson Cancer Center, Houston, Texas (A.B.H.).
Rose K LaiHospital of the University of Pennsylvania, Philadelphia, Pennsylvania (J.S.); The Neurological Institute of Columbia University, New York, New York (R.K.L.); Stanford Cancer Center, Stanford, California (L.D.R.); Duke University Medical Center, Durham, North Carolina (D.A.R., G.E.A., D.D.B., J.H.S.); Evanston Northwestern Healthcare, Evanston, Illinois (N.A.P.); University of Texas M.D. Anderson Cancer Center, Houston, Texas (M.D.G.); University of Washington School of Medicine, Seattle, Washington (M.M.M.); Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah (R.J.); Yale University School of Medicine, New Haven, Connecticut (J.M.B); University Hospital-Case Medical Center & Case Comprehensive Cancer Center, Cleveland, Ohio (A.S.); Scott Cruickshank & Associates, Inc., Santa Barbara, C alifornia (S.C.); Celldex Therapeutics, Inc., Hampton, New Jersey (J.A.G., T.K., T.A.D.); University of Texas M.D. Anderson Cancer Center, Houston, Texas (A.B.H.).
Lawrence D RechtHospital of the University of Pennsylvania, Philadelphia, Pennsylvania (J.S.); The Neurological Institute of Columbia University, New York, New York (R.K.L.); Stanford Cancer Center, Stanford, California (L.D.R.); Duke University Medical Center, Durham, North Carolina (D.A.R., G.E.A., D.D.B., J.H.S.); Evanston Northwestern Healthcare, Evanston, Illinois (N.A.P.); University of Texas M.D. Anderson Cancer Center, Houston, Texas (M.D.G.); University of Washington School of Medicine, Seattle, Washington (M.M.M.); Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah (R.J.); Yale University School of Medicine, New Haven, Connecticut (J.M.B); University Hospital-Case Medical Center & Case Comprehensive Cancer Center, Cleveland, Ohio (A.S.); Scott Cruickshank & Associates, Inc., Santa Barbara, C alifornia (S.C.); Celldex Therapeutics, Inc., Hampton, New Jersey (J.A.G., T.K., T.A.D.); University of Texas M.D. Anderson Cancer Center, Houston, Texas (A.B.H.).
David A ReardonHospital of the University of Pennsylvania, Philadelphia, Pennsylvania (J.S.); The Neurological Institute of Columbia University, New York, New York (R.K.L.); Stanford Cancer Center, Stanford, California (L.D.R.); Duke University Medical Center, Durham, North Carolina (D.A.R., G.E.A., D.D.B., J.H.S.); Evanston Northwestern Healthcare, Evanston, Illinois (N.A.P.); University of Texas M.D. Anderson Cancer Center, Houston, Texas (M.D.G.); University of Washington School of Medicine, Seattle, Washington (M.M.M.); Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah (R.J.); Yale University School of Medicine, New Haven, Connecticut (J.M.B); University Hospital-Case Medical Center & Case Comprehensive Cancer Center, Cleveland, Ohio (A.S.); Scott Cruickshank & Associates, Inc., Santa Barbara, C alifornia (S.C.); Celldex Therapeutics, Inc., Hampton, New Jersey (J.A.G., T.K., T.A.D.); University of Texas M.D. Anderson Cancer Center, Houston, Texas (A.B.H.).
Nina A PaleologosHospital of the University of Pennsylvania, Philadelphia, Pennsylvania (J.S.); The Neurological Institute of Columbia University, New York, New York (R.K.L.); Stanford Cancer Center, Stanford, California (L.D.R.); Duke University Medical Center, Durham, North Carolina (D.A.R., G.E.A., D.D.B., J.H.S.); Evanston Northwestern Healthcare, Evanston, Illinois (N.A.P.); University of Texas M.D. Anderson Cancer Center, Houston, Texas (M.D.G.); University of Washington School of Medicine, Seattle, Washington (M.M.M.); Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah (R.J.); Yale University School of Medicine, New Haven, Connecticut (J.M.B); University Hospital-Case Medical Center & Case Comprehensive Cancer Center, Cleveland, Ohio (A.S.); Scott Cruickshank & Associates, Inc., Santa Barbara, C alifornia (S.C.); Celldex Therapeutics, Inc., Hampton, New Jersey (J.A.G., T.K., T.A.D.); University of Texas M.D. Anderson Cancer Center, Houston, Texas (A.B.H.).
Morris D GrovesHospital of the University of Pennsylvania, Philadelphia, Pennsylvania (J.S.); The Neurological Institute of Columbia University, New York, New York (R.K.L.); Stanford Cancer Center, Stanford, California (L.D.R.); Duke University Medical Center, Durham, North Carolina (D.A.R., G.E.A., D.D.B., J.H.S.); Evanston Northwestern Healthcare, Evanston, Illinois (N.A.P.); University of Texas M.D. Anderson Cancer Center, Houston, Texas (M.D.G.); University of Washington School of Medicine, Seattle, Washington (M.M.M.); Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah (R.J.); Yale University School of Medicine, New Haven, Connecticut (J.M.B); University Hospital-Case Medical Center & Case Comprehensive Cancer Center, Cleveland, Ohio (A.S.); Scott Cruickshank & Associates, Inc., Santa Barbara, C alifornia (S.C.); Celldex Therapeutics, Inc., Hampton, New Jersey (J.A.G., T.K., T.A.D.); University of Texas M.D. Anderson Cancer Center, Houston, Texas (A.B.H.).
Maciej M MrugalaHospital of the University of Pennsylvania, Philadelphia, Pennsylvania (J.S.); The Neurological Institute of Columbia University, New York, New York (R.K.L.); Stanford Cancer Center, Stanford, California (L.D.R.); Duke University Medical Center, Durham, North Carolina (D.A.R., G.E.A., D.D.B., J.H.S.); Evanston Northwestern Healthcare, Evanston, Illinois (N.A.P.); University of Texas M.D. Anderson Cancer Center, Houston, Texas (M.D.G.); University of Washington School of Medicine, Seattle, Washington (M.M.M.); Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah (R.J.); Yale University School of Medicine, New Haven, Connecticut (J.M.B); University Hospital-Case Medical Center & Case Comprehensive Cancer Center, Cleveland, Ohio (A.S.); Scott Cruickshank & Associates, Inc., Santa Barbara, C alifornia (S.C.); Celldex Therapeutics, Inc., Hampton, New Jersey (J.A.G., T.K., T.A.D.); University of Texas M.D. Anderson Cancer Center, Houston, Texas (A.B.H.).
Randy JensenHospital of the University of Pennsylvania, Philadelphia, Pennsylvania (J.S.); The Neurological Institute of Columbia University, New York, New York (R.K.L.); Stanford Cancer Center, Stanford, California (L.D.R.); Duke University Medical Center, Durham, North Carolina (D.A.R., G.E.A., D.D.B., J.H.S.); Evanston Northwestern Healthcare, Evanston, Illinois (N.A.P.); University of Texas M.D. Anderson Cancer Center, Houston, Texas (M.D.G.); University of Washington School of Medicine, Seattle, Washington (M.M.M.); Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah (R.J.); Yale University School of Medicine, New Haven, Connecticut (J.M.B); University Hospital-Case Medical Center & Case Comprehensive Cancer Center, Cleveland, Ohio (A.S.); Scott Cruickshank & Associates, Inc., Santa Barbara, C alifornia (S.C.); Celldex Therapeutics, Inc., Hampton, New Jersey (J.A.G., T.K., T.A.D.); University of Texas M.D. Anderson Cancer Center, Houston, Texas (A.B.H.).
Joachim M BaehringHospital of the University of Pennsylvania, Philadelphia, Pennsylvania (J.S.); The Neurological Institute of Columbia University, New York, New York (R.K.L.); Stanford Cancer Center, Stanford, California (L.D.R.); Duke University Medical Center, Durham, North Carolina (D.A.R., G.E.A., D.D.B., J.H.S.); Evanston Northwestern Healthcare, Evanston, Illinois (N.A.P.); University of Texas M.D. Anderson Cancer Center, Houston, Texas (M.D.G.); University of Washington School of Medicine, Seattle, Washington (M.M.M.); Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah (R.J.); Yale University School of Medicine, New Haven, Connecticut (J.M.B); University Hospital-Case Medical Center & Case Comprehensive Cancer Center, Cleveland, Ohio (A.S.); Scott Cruickshank & Associates, Inc., Santa Barbara, C alifornia (S.C.); Celldex Therapeutics, Inc., Hampton, New Jersey (J.A.G., T.K., T.A.D.); University of Texas M.D. Anderson Cancer Center, Houston, Texas (A.B.H.).
Andrew SloanHospital of the University of Pennsylvania, Philadelphia, Pennsylvania (J.S.); The Neurological Institute of Columbia University, New York, New York (R.K.L.); Stanford Cancer Center, Stanford, California (L.D.R.); Duke University Medical Center, Durham, North Carolina (D.A.R., G.E.A., D.D.B., J.H.S.); Evanston Northwestern Healthcare, Evanston, Illinois (N.A.P.); University of Texas M.D. Anderson Cancer Center, Houston, Texas (M.D.G.); University of Washington School of Medicine, Seattle, Washington (M.M.M.); Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah (R.J.); Yale University School of Medicine, New Haven, Connecticut (J.M.B); University Hospital-Case Medical Center & Case Comprehensive Cancer Center, Cleveland, Ohio (A.S.); Scott Cruickshank & Associates, Inc., Santa Barbara, C alifornia (S.C.); Celldex Therapeutics, Inc., Hampton, New Jersey (J.A.G., T.K., T.A.D.); University of Texas M.D. Anderson Cancer Center, Houston, Texas (A.B.H.).
Gary E ArcherHospital of the University of Pennsylvania, Philadelphia, Pennsylvania (J.S.); The Neurological Institute of Columbia University, New York, New York (R.K.L.); Stanford Cancer Center, Stanford, California (L.D.R.); Duke University Medical Center, Durham, North Carolina (D.A.R., G.E.A., D.D.B., J.H.S.); Evanston Northwestern Healthcare, Evanston, Illinois (N.A.P.); University of Texas M.D. Anderson Cancer Center, Houston, Texas (M.D.G.); University of Washington School of Medicine, Seattle, Washington (M.M.M.); Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah (R.J.); Yale University School of Medicine, New Haven, Connecticut (J.M.B); University Hospital-Case Medical Center & Case Comprehensive Cancer Center, Cleveland, Ohio (A.S.); Scott Cruickshank & Associates, Inc., Santa Barbara, C alifornia (S.C.); Celldex Therapeutics, Inc., Hampton, New Jersey (J.A.G., T.K., T.A.D.); University of Texas M.D. Anderson Cancer Center, Houston, Texas (A.B.H.).
Darell D BignerHospital of the University of Pennsylvania, Philadelphia, Pennsylvania (J.S.); The Neurological Institute of Columbia University, New York, New York (R.K.L.); Stanford Cancer Center, Stanford, California (L.D.R.); Duke University Medical Center, Durham, North Carolina (D.A.R., G.E.A., D.D.B., J.H.S.); Evanston Northwestern Healthcare, Evanston, Illinois (N.A.P.); University of Texas M.D. Anderson Cancer Center, Houston, Texas (M.D.G.); University of Washington School of Medicine, Seattle, Washington (M.M.M.); Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah (R.J.); Yale University School of Medicine, New Haven, Connecticut (J.M.B); University Hospital-Case Medical Center & Case Comprehensive Cancer Center, Cleveland, Ohio (A.S.); Scott Cruickshank & Associates, Inc., Santa Barbara, C alifornia (S.C.); Celldex Therapeutics, Inc., Hampton, New Jersey (J.A.G., T.K., T.A.D.); University of Texas M.D. Anderson Cancer Center, Houston, Texas (A.B.H.).
Scott CruickshankHospital of the University of Pennsylvania, Philadelphia, Pennsylvania (J.S.); The Neurological Institute of Columbia University, New York, New York (R.K.L.); Stanford Cancer Center, Stanford, California (L.D.R.); Duke University Medical Center, Durham, North Carolina (D.A.R., G.E.A., D.D.B., J.H.S.); Evanston Northwestern Healthcare, Evanston, Illinois (N.A.P.); University of Texas M.D. Anderson Cancer Center, Houston, Texas (M.D.G.); University of Washington School of Medicine, Seattle, Washington (M.M.M.); Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah (R.J.); Yale University School of Medicine, New Haven, Connecticut (J.M.B); University Hospital-Case Medical Center & Case Comprehensive Cancer Center, Cleveland, Ohio (A.S.); Scott Cruickshank & Associates, Inc., Santa Barbara, C alifornia (S.C.); Celldex Therapeutics, Inc., Hampton, New Jersey (J.A.G., T.K., T.A.D.); University of Texas M.D. Anderson Cancer Center, Houston, Texas (A.B.H.).
Jennifer A GreenHospital of the University of Pennsylvania, Philadelphia, Pennsylvania (J.S.); The Neurological Institute of Columbia University, New York, New York (R.K.L.); Stanford Cancer Center, Stanford, California (L.D.R.); Duke University Medical Center, Durham, North Carolina (D.A.R., G.E.A., D.D.B., J.H.S.); Evanston Northwestern Healthcare, Evanston, Illinois (N.A.P.); University of Texas M.D. Anderson Cancer Center, Houston, Texas (M.D.G.); University of Washington School of Medicine, Seattle, Washington (M.M.M.); Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah (R.J.); Yale University School of Medicine, New Haven, Connecticut (J.M.B); University Hospital-Case Medical Center & Case Comprehensive Cancer Center, Cleveland, Ohio (A.S.); Scott Cruickshank & Associates, Inc., Santa Barbara, C alifornia (S.C.); Celldex Therapeutics, Inc., Hampton, New Jersey (J.A.G., T.K., T.A.D.); University of Texas M.D. Anderson Cancer Center, Houston, Texas (A.B.H.).
Tibor KelerHospital of the University of Pennsylvania, Philadelphia, Pennsylvania (J.S.); The Neurological Institute of Columbia University, New York, New York (R.K.L.); Stanford Cancer Center, Stanford, California (L.D.R.); Duke University Medical Center, Durham, North Carolina (D.A.R., G.E.A., D.D.B., J.H.S.); Evanston Northwestern Healthcare, Evanston, Illinois (N.A.P.); University of Texas M.D. Anderson Cancer Center, Houston, Texas (M.D.G.); University of Washington School of Medicine, Seattle, Washington (M.M.M.); Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah (R.J.); Yale University School of Medicine, New Haven, Connecticut (J.M.B); University Hospital-Case Medical Center & Case Comprehensive Cancer Center, Cleveland, Ohio (A.S.); Scott Cruickshank & Associates, Inc., Santa Barbara, C alifornia (S.C.); Celldex Therapeutics, Inc., Hampton, New Jersey (J.A.G., T.K., T.A.D.); University of Texas M.D. Anderson Cancer Center, Houston, Texas (A.B.H.).
Thomas A DavisHospital of the University of Pennsylvania, Philadelphia, Pennsylvania (J.S.); The Neurological Institute of Columbia University, New York, New York (R.K.L.); Stanford Cancer Center, Stanford, California (L.D.R.); Duke University Medical Center, Durham, North Carolina (D.A.R., G.E.A., D.D.B., J.H.S.); Evanston Northwestern Healthcare, Evanston, Illinois (N.A.P.); University of Texas M.D. Anderson Cancer Center, Houston, Texas (M.D.G.); University of Washington School of Medicine, Seattle, Washington (M.M.M.); Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah (R.J.); Yale University School of Medicine, New Haven, Connecticut (J.M.B); University Hospital-Case Medical Center & Case Comprehensive Cancer Center, Cleveland, Ohio (A.S.); Scott Cruickshank & Associates, Inc., Santa Barbara, C alifornia (S.C.); Celldex Therapeutics, Inc., Hampton, New Jersey (J.A.G., T.K., T.A.D.); University of Texas M.D. Anderson Cancer Center, Houston, Texas (A.B.H.).
Amy B HeimbergerHospital of the University of Pennsylvania, Philadelphia, Pennsylvania (J.S.); The Neurological Institute of Columbia University, New York, New York (R.K.L.); Stanford Cancer Center, Stanford, California (L.D.R.); Duke University Medical Center, Durham, North Carolina (D.A.R., G.E.A., D.D.B., J.H.S.); Evanston Northwestern Healthcare, Evanston, Illinois (N.A.P.); University of Texas M.D. Anderson Cancer Center, Houston, Texas (M.D.G.); University of Washington School of Medicine, Seattle, Washington (M.M.M.); Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah (R.J.); Yale University School of Medicine, New Haven, Connecticut (J.M.B); University Hospital-Case Medical Center & Case Comprehensive Cancer Center, Cleveland, Ohio (A.S.); Scott Cruickshank & Associates, Inc., Santa Barbara, C alifornia (S.C.); Celldex Therapeutics, Inc., Hampton, New Jersey (J.A.G., T.K., T.A.D.); University of Texas M.D. Anderson Cancer Center, Houston, Texas (A.B.H.).
John H SampsonHospital of the University of Pennsylvania, Philadelphia, Pennsylvania (J.S.); The Neurological Institute of Columbia University, New York, New York (R.K.L.); Stanford Cancer Center, Stanford, California (L.D.R.); Duke University Medical Center, Durham, North Carolina (D.A.R., G.E.A., D.D.B., J.H.S.); Evanston Northwestern Healthcare, Evanston, Illinois (N.A.P.); University of Texas M.D. Anderson Cancer Center, Houston, Texas (M.D.G.); University of Washington School of Medicine, Seattle, Washington (M.M.M.); Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah (R.J.); Yale University School of Medicine, New Haven, Connecticut (J.M.B); University Hospital-Case Medical Center & Case Comprehensive Cancer Center, Cleveland, Ohio (A.S.); Scott Cruickshank & Associates, Inc., Santa Barbara, C alifornia (S.C.); Celldex Therapeutics, Inc., Hampton, New Jersey (J.A.G., T.K., T.A.D.); University of Texas M.D. Anderson Cancer Center, Houston, Texas (A.B.H.).
Celldex Therapeutics (United States) · USDuke University · USCase Western Reserve University · USDana-Farber Cancer Institute · USRush University · USSouthern California University for Professional Studies · USStanford University · USTexas Oncology · USThe University of Texas MD Anderson Cancer Center · USUniversity of Utah · USUniversity of Washington · USYale University · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MNCI NIH HHS P30 CA016672
Abstract
backgroundThe epidermal growth factor receptor variant III deletion mutation, EGFRvIII, is expressed in ∼30% of primary glioblastoma and linked to poor long-term survival. Rindopepimut consists of the unique EGFRvIII peptide sequence conjugated to keyhole limpet hemocyanin. In previous phase II trials (ACTIVATE/ACT II), rindopepimut was well tolerated with robust EGFRvIII-specific immune responses and promising progression-free and overall survival. This multicenter, single-arm phase II clinical trial (ACT III) was performed to confirm these results.
methodsRindopepimut and standard adjuvant temozolomide chemotherapy were administered to 65 patients with newly diagnosed EGFRvIII-expressing (EGFRvIII+) glioblastoma after gross total resection and chemoradiation.
resultsProgression-free survival at 5.5 months (∼8.5 mo from diagnosis) was 66%. Relative to study entry, median overall survival was 21.8 months, and 36-month overall survival was 26%. Extended rindopepimut vaccination (up to 3.5+ years) was well tolerated. Grades 1-2 injection site reactions were frequent. Anti-EGFRvIII antibody titers increased ≥4-fold in 85% of patients, and increased with duration of treatment. EGFRvIII was eliminated in 4/6 (67%) tumor samples obtained after >3 months of therapy.
conclusionsThis study confirms, in a multicenter setting, the preliminary results seen in previous phase II trials of rindopepimut. A pivotal, double-blind, randomized, phase III trial ("ACT IV") is under way.
Indexed as
AdultAgedAged, 80 and overAntineoplastic AgentsBrain NeoplasmsCancer VaccinesChemoradiotherapy, AdjuvantDacarbazineDisease-Free SurvivalErbB ReceptorsFemaleGlioblastomaHumansKaplan-Meier EstimateMaleMiddle AgedAntineoplastic AgentsCancer VaccinesDacarbazineepidermal growth factor receptor VIIIErbB ReceptorsrindopepimutTemozolomideVaccines, SubunitACT IIIEGFRvIIIglioblastomagliomarindopepimut
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT00458601ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.